New hope for older leukemia patients: drug combo targets hard-to-treat AML
NCT ID NCT03513484
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This study tests a new combination of two drugs, nintedanib and azacitidine, in older adults with acute myeloid leukemia (AML) who cannot have or do not want standard intensive chemotherapy. The goal is to find the best dose of nintedanib when given with azacitidine and to see what side effects occur. Participants receive treatment for up to 6 cycles, and may continue if it helps, until their leukemia worsens or side effects become too serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.